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Microbeam radiation treatment (MRT) using synchrotron
radiation has shown great promise in the treatment of brain
tumors, with a demonstrated ability to eradicate the tumor
while sparing normal tissue in small animal models. With the
goal of expediting the advancement of MRT research beyond
the limited number of synchrotron facilities in the world, we
recently developed a compact laboratory-scale microbeam
irradiator using carbon nanotube (CNT) field emission-based
X-ray source array technology. The focus of this study is to
evaluate the effects of the microbeam radiation generated by
this compact irradiator in terms of tumor control and normal
tissue damage in a mouse brain tumor model. Mice with
U87MG human glioblastoma were treated with sham
irradiation, low-dose MRT, high-dose MRT or 10 Gy broad-
beam radiation treatment (BRT). The microbeams were 280
lm wide and spaced at 900 lm center-to-center with peak
dose at either 48 Gy (low-dose MRT) or 72 Gy (high-dose
MRT). Survival studies showed that the mice treated with
both MRT protocols had a significantly extended life span
compared to the untreated control group (31.4 and 48.5% of
life extension for low- and high-dose MRT, respectively) and
had similar survival to the BRT group. Immunostaining on
MRT mice demonstrated much higher DNA damage and
apoptosis level in tumor tissue compared to the normal brain
tissue. Apoptosis in normal tissue was significantly lower in
the low-dose MRT group compared to that in the BRT group
at 48 h postirradiation. Interestingly, there was a significantly
higher level of cell proliferation in the MRT-treated normal
tissue compared to that in the BRT-treated mice, indicating
rapid normal tissue repairing process after MRT. Microbeam
radiation exposure on normal brain tissue causes little
apoptosis and no macrophage infiltration at 30 days after
exposure. This study is the first biological assessment on
MRT effects using the compact CNT-based irradiator. It
provides an alternative technology that can enable wide-
spread MRT research on mechanistic studies using a
preclinical model, as well as further translational research
towards clinical applications.  2015 by Radiation Research Society
INTRODUCTION
Despite recent developments in the treatment of glioblas-
toma multiforme (GBM) the median survival for glioblas-
toma is still limited to 12 months on average (1, 2). While
radiation therapy is one of the primary treatments for brain
tumors, effective brain tumor control is often limited by the
risk of collateral radiation-induced damage to the surround-
ing normal brain tissue (3, 4). Therefore, reducing normal
tissue toxicity while enhancing tumor control, and improv-
ing the overall therapeutic efficacy, remains a goal in
radiation therapy.
Microbeam radiation treatment (MRT) is a unique form of
spatially fractioned radiation therapy that uses parallel thin
planar X-ray beams for treatment. In many preclinical
studies, MRT has demonstrated effective tumor cell killing,
while sparing normal tissue (5–11). However, given the
small number of synchrotron radiation facilities around the
world that are available to provide MRT, advances in MRT
and potential clinical translation are greatly hindered. To
promote widespread MRT research in the scientific
community, our group recently developed a compact X-
ray microbeam irradiator based on carbon nanotube (CNT)
field emission technology (12, 13). The compact system is
not designed to reproduce the exact radiation profile and
dosimetry generated by the large synchrotron-based MRT
facilities, but to investigate the microbeam radiation
dosimetry required to produce similar MRT radiobiological
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outcomes. The first preclinical prototype we developed (Fig.
1) contains a CNT field emission cathode array and a
tungsten anode with a long and narrow focal line to produce
optimally distributed X-ray microbeam with adjustable
beam width (14). The distributed CNT X-ray source design
maximizes microbeam dose rate by spreading the total
thermal power to a long focal track (0.142 3 160 mm), and
this cannot be achieved by the small focal point design used
in most conventional X-ray tubes. Our compact microbeam
system is different from the synchrotron irradiation system,
since it electronically controls the radiation and thus allows
real-time gated radiation delivery using respiratory or
cardiac signals to accurately deliver the radiation under
organ motions (15). An image-guided MRT protocol has
been established for mouse brain tumor treatment, where
magnetic resonance images were registered to the on-board
X-ray radiography images of mouse brain to guide the
delivery of microbeam radiation to the brain tumor with an
average 450 lm accuracy (16). The current study used the
same image-guided MRT protocol reported earlier, and
aimed to evaluate radiobiological effects from MRT.
In this radiobiologically focused study, we evaluated the
effects of MRT on both brain tumor and normal brain tissue
in a U87MG human glioblastoma-bearing mouse model
using this compact CNT-based microbeam irradiator.
Survival studies were conducted and tumor volume was
monitored using MRI after radiation treatment. Immuno-
staining of c-H2AX, caspase-3, Ki-67 and F4/80 proteins
was performed at different time points after MRT to assess
radiation-induced DNA double-strand breaks (DSBs),
apoptosis, cell proliferation and neuroinflammation, respec-
tively. MRT effects on normal mice without tumor were
also evaluated at acute (24 h) and delayed (day 30) phases
after MRT. This study is the first to characterize the MRT
effects on brain tumor and normal tissue using the compact
CNT-based image-guided MRT system.
MATERIALS AND METHODS
Brain Tumor Mouse Model
Male athymic nude mice (4–6 weeks old) were used for brain tumor
inoculation. U87MG human glioblastoma tumor cells were obtained
from Dr. C. Ryan Miller, University of North Carolina (UNC; Chapel
Hill, NC) and maintained in our laboratory. About 2 3 105 cells in 5 ll
culture media mixed with 5% methylcellulose were injected into the
forebrain of mice using the stereotaxic technique at 1 mm anterior, 2
mm lateral to the bregma and 4 mm deep from the surface to form the
orthotopic xenograft glioblastoma mouse model. Three weeks after
tumor cell injection, the mice were brought to the Imaging Core Facility
for MRI and subsequent radiation treatment. All animal handling and
experimental procedures in the study were approved by the Institutional
Animal Care and Use Committee at University of North Carolina.
Magnetic Resonance Imaging
Mouse brain MRIs were performed on a small animal 9.4 Tesla
MRI system (Bruker Inc., Billerica, MA) at the UNC Small Animal
Imaging Core Facility. T2-weighted images were acquired using a
rapid acquisition with refocused echoes (RARE) sequence with the
FIG. 1. System structure and components of the compact carbon-
nanotube-based (CNT) microbeam irradiator. Panel A: MicroCT
integrated microbeam irradiator setup in the laboratory. Panel B:
Structure diagram of the microbeam irradiator. Panel C: Cartoon
diagram demonstrating three arrays of planar microbeams applied on
mouse head for treatment [modified and used with permission, Zhang
et al. Phys Med Biol 2014; 59:1283–303 (16)].
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following parameters: TE/TR¼ 22/3,400 ms, 256 3 256 matrix size,
0.5 mm slice thickness and 100 lm in-plane resolutions. Tumor
volume was measured by manually demarcating the tumor region on
each MRI slice using ImageJ (version 1.46r, imagej.nih.gov/ij; ImageJ
Software, National Institutes of Health, Bethesda, MD). Mice were
initially imaged at 3 weeks after tumor cell inoculation for tumor
localization and volume measurement. After irradiation, mice were
imaged using the same MRI protocol weekly for two weeks after MRT
to monitor changes in tumor volume.
Microbeam Radiation Treatment
Microbeam irradiation to the mouse brain was performed using the
prototype compact CNT-based MRT system. Figure 1 shows the system
diagram and an illustration of radiation beam delivery to the mouse
head. The microbeam irradiator runs at a constant anode voltage of 160
kVp. The system was calibrated with ion chamber dosimeter and
Gafchromice EBT2 film with multichannel dosimetry. Detailed
dosimetry determination can be found in our previously reported work
(16, 17). The average dose rate at the mouse brain entrance plane has
been measured to be 1.2 Gy/min. Peak dose at either 48 or 72 Gy was
used for the low- or high-dose MRT protocol to irradiate the mouse
brain. Each microbeam was 280 lm wide and 160 mm long, spaced at
900 lm center-to-center distance. Three microbeams of radiation were
delivered unidirectionally across the mouse brain in the low-dose MRT
group, while two microbeams were delivered in the high-dose MRT
group, so the total integrated doses were the same in the two MRT
groups. The orientation of the beam is shown in Fig. 1C. Microbeam
profiles were validated by Gafchromic EBT2 films placed at the
entrance and exit plane of the mouse head.
Image-guided MRT was performed according to previously
reported protocol (16). Briefly, mice first underwent MRI for tumor
localization, and were then transported to the radiation laboratory the
next day for MRT. For radiation treatment, the animal was
anesthetized with isoflurane (1.5%) mixed with 100% oxygen gas
and placed in prone position on the mouse cradle for X-ray
radiography imaging. MR images of the mouse head were then
registered to the X-ray images using rigid body registration. The
relative position of the tumor to the landmarks on the imaging bed was
then determined from the registered image, and subsequently used to
maneuver the imaging bed to the treatment position with a high-
precision translation stage (Velmex Inc., Bloomfield, NY), so that the
microbeam radiation could be accurately delivered to the tumor target.
A total of 57 tumor-bearing mice and six normal mice were treated
with MRT for survival and immunostaining studies. In the survival
study, 42 animals were distributed into three groups based on tumor
size so that the average tumor size of each group was not statistically
different from the other groups before treatment. The three groups
included a sham-irradiated group (isoflurane only, no irradiation, n¼
19), a low-dose MRT group treated with peak radiation dose of 48 Gy
(n¼ 19) and a high-dose MRT group treated with peak radiation dose
of 72 Gy (n¼ 4). Another batch of tumor-bearing mice (n¼ 15) and
normal mice (n¼ 6) were used for immunostaining study after MRT
(see the Immunostaining section).
Conventional Broad-Beam Radiation Treatment
A separate group of U87MG tumor-bearing mice (n ¼ 17)
underwent conventional broad-beam radiation treatment. Mice were
anesthetized with the same isoflurane inhalation method and placed on
the radiation treating bed. Radiation of 10 Gy was delivered to the
mouse brain using a clinical linear accelerator (Siemens Primus, 6 MV
photon beam). The radiation field is 1 3 1 cm centered on the mouse
brain. The treatment dose was computed using in-house clinical
treatment planning software PLUNC.
After irradiation, one group of mice (n ¼ 9) was used to study
survival by recording animal life span after treatment. Another group
of mice (n¼ 8) was used for histological analysis by collecting brain
tissue at 24 h (n ¼ 4) and 48 h (n ¼ 4) after irradiation.
Immunostaining and Quantification
Tumor-bearing mice were euthanized at 1, 4, 24, 48 h and day 7 after
low-dose MRT or at 24 and 48 h after BRT. Brains were collected and
fixed in formalin for 48 h. The fixed brains were then dehydrated,
embedded in paraffin and cut into 5 lm brain sections in sagittal plane
perpendicular to the microbeam direction near tumor location. The
cutting location was determined from MR images. Three consecutive
brain sections were used for staining with antibodies to phosphorylated
histone c-H2AX, cleaved caspase-3 and Ki-67 protein to assess DNA
DSBs, apoptosis and cell proliferation, which have been well
documented in the literature (18, 19). All immunostaining procedures
were conducted in the Tissue Pathology Core Facility with standardized
staining protocol for all the tissue slides and positive/negative slides.
For staining, tissue sections were deparaffinized followed by antigen
retrieval with citrate buffer, and incubated with primary antibodies to
one of the following proteins: c-H2AX (rabbit anti-mouse c-H2AX
antibody; Cell Signaling Technologyt, Danvers, MA), 1:1,000 dilution,
8 h incubation; cleaved caspase-3 (Biocare Medical Inc., Concord, CA),
1:400 dilution, 4 h incubation); and Ki-67 (BD Pharmingene, San
Diego, CA), 1:500 dilution, 4 h incubation. The sections were then
incubated with an appropriate secondary antibody followed with
tyramide Cy5 amplification (PerkinElmert Inc., Boston, MA). To stain
nuclei and preserve the fluorescent signals, ProLongt Gold antifade
reagent containing 4,6-diamidino-2-phenylindole (DAPI) was used
(Molecular Probest, Eugene, OR) on stained sections. The section was
then scanned in the DAPI and Cy5 channels using a high-resolution
(203 objectives) fluorescence slide scanner system (ScanScope FL
scanner, Aperiot, Vista, CA). Immunostaining of c-H2AX, caspase-3
and F4/80 (microglia and macrophage marker) was conducted on
normal mouse brain tissues at 24 h and at day 30 after irradiation to
assess both acute and chronic damage on normal tissue from microbeam
radiation.
The c-H2AX quantification method was based on a previously
published study (20) where the positively stained c-H2AX fluorescence
signal in nuclei was confirmed to be correlated with the expressed c-
H2AX protein level measured by Western blot. To quantify the c-
H2AX signal, cell nucleus region was first extracted from the DAPI
nuclei counterstaining channel and masked to the c-H2AX Cy5
fluorescence channel. Since c-H2AX foci were present solely in cell
nuclei, only signals inside the cell nuclei were measured. This method
prevented the possibility of bias caused by different cell density in
tumor and normal brain tissue. Five regions were defined based on the
c-H2AX staining images: radiation beam passing regions on the tumor
tissue (tumor peak region) and on the contralateral normal brain tissue
(normal peak region), beam valley regions on the tumor tissue (tumor
valley region) and normal brain tissue (normal valley region) and
regions away from the MRT field as normal tissue background (normal
tissue region). Average fluorescence signal on the masked nuclei area
was measured as mean c-H2AX signal for the five regions.
Apoptosis was detected using cleaved caspase-3 staining. The
caspase-3 images were first aligned with the c-H2AX images from the
neighboring section using ImageJ software (version 1.47), and the five
tissue regions defined in the c-H2AX images were mapped to the
caspase-3 images. Numbers of positively stained cells in peak and
valley regions were counted in tumor and normal tissue. The number
of positively caspase-3 stained cells per mm2 was calculated as a
quantitative measure of the apoptosis level after irradiation.
Immunofluorescence staining on Ki-67 protein was conducted on
irradiated brain sections to measure cell proliferation. One tumor section
from a sham-irradiated mouse was always included as a positive control.
Area fraction of positive Ki-67 staining on the nuclei area was measured
in the tumor peak and tumor valley regions. The ratio between irradiated
tumor tissue and nonirradiated positive control was reported as the
proliferation ratio. In the contralateral normal brain tissue, the number of
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positively stained cells on the irradiated region in the middle of striatum
of MRT mice and the same sized region of BRT mice was measured as
the parameter to quantify normal tissue proliferation.
Statistical Analysis
Data from the survival studies were analyzed using the Kaplan-
Meier method (GraphPad Prism software; GraphPad Software Inc.,
LaJolla, CA). The median survival time and the percentage of
extended life span were reported. The extended life span is defined as
the ratio of the extension of median survival time in the treated group
to the median survival time in the control group. Survival curves were
compared using the logrank test between each group. Data on
expression level of c-H2AX, caspase-3 and Ki-67 were presented as
mean 6 SEM. Differences between expression level on tumor and
normal tissue at different time points after MRT were compared using
t test. P , 0.05 was considered significant.
RESULTS
MRT on Mouse Brain and Radiation Dose Verification
The delivered microbeam radiation dose was verified using
Gafchromic films placed at the entrance and exit planes of the
mouse head. The beam width (full width at half maximum,
FWHM) was 280 lm at the entrance plane on the top of the
mouse brain and 380 lm at the exit plane at the bottom of the
head. The peak-to-valley-dose-ratio (PVDR) was measured
to be 16 at the entrance plane and decreased to 14 at the exit
plane (see Fig. 2A and B).
Using c-H2AX staining on irradiated brain tissue, we
were able to clearly show the radiation beam tracks in
normal brain tissue (Fig. 2C) and in tumor-bearing mouse
brain (Fig. 2D). The center-to-center distance between two
adjacent tracks in the c-H2AX image was measured to be
782.2 lm on average, which was very close to the
prescribed beam pitch of 900 lm when taking into
consideration a ;20% tissue shrinkage during histology
processing (21). The FWHM of the track was 343.4 lm in
the c-H2AX staining images, which was wider than the
radiation beam width at the exit plane, considering the tissue
shrinkage. This was possibly due to the nonlinear response
between radiation dose and c-H2AX expression at doses
above 10 Gy (22), causing widened FWHM measurement
on c-H2AX expression tracks.
MRT on Overall Survival and Tumor Control
Median survival time (MST) for the sham-irradiated group
was 35 days after tumor inoculation [95% CI¼ (34.4, 35.6)].
The MST for animals treated with low-dose MRT, high-dose
MRT and BRT was 46 (43.2, 48.8) days, 52 (40.8, 63.2) days
and 52 (50.9, 53.1) days (values shown in parentheses are
95% confidence interval) respectively, as shown in Fig. 3.
Both low-dose and high-dose MRT significantly extended
mouse life span (P , 0.001, logrank test) by 31.4 and 48.5%,
respectively. The extended life span for the BRT group was
48.5%. There was no significant difference among the BRT
group and the two MRT groups in terms of median survival
time (P . 0.05, logrank test).
Tumor-bearing mice underwent MRI scans and tumor
volumes were measured over time before and after radiation
treatment. Figure 4A shows typical T2 weighted MR
images from each group at different time points. Absolute
tumor volume measurement for each group is shown in Fig.
4B. The volume change ratio, i.e., the tumor volume
increase from the initial volume before MRT divided by the
initial volume [(Vt – V0)/V0], was calculated for individual
animals and plotted in Fig. 4C. At one week after MRT, the
sham-irradiated group had 10.0 6 2.1 fold of increase in
tumor volume, while the low-dose and high-dose MRT
groups had only 4.1 6 1.1 fold and 1.5 6 0.8 fold of
volume increase, respectively, demonstrating significant
inhibition of tumor growth after MRT (P , 0.01 for both
MRT groups and the sham-irradiated group). At day 14
after MRT, tumor volume was 51.7 6 16.0, 37.0 6 9.4 and
14.3 6 4.1 fold of increase in the sham-irradiated, low-dose
and high-dose MRT groups, respectively. Tumor growth
was continuously suppressed (.10 times) by the high-dose
MRT at a significant level (P¼ 0.04), while only a trend of
inhibition was observed with low-dose MRT (P ¼ 0.21).
MRT on DNA Damage and its Dynamics
Expression of c-H2AX was measured at 1, 4, 24, 48 h and
day 7 after MRT. Figure 5 shows c-H2AX staining on both
tumor and normal tissue in the contralateral hemisphere.
Strong expression was observed as early as 1 h postirradi-
ation on both tumor and normal tissue on the radiation beam
passing regions, indicating radiation-induced DNA DSBs.
The expression reduced over time from 1 h to day 7 after
irradiation on both tumor and normal tissue, suggesting the
ongoing repair process in response to DNA damage. By day
7 after irradiation, the c-H2AX signal in the normal valley
region dropped to background level, but the c-H2AX signal
in the tumor tissue did not. Average c-H2AX signal in nuclei
was quantified in the five regions, defined in the Materials
and Methods section. In the radiation beam passing region,
there was a trend of higher c-H2AX level in tumor (tumor
peak) compared to that in the normal brain tissue (normal
peak) at all time points, however, it was not statistically
significant, possibly due to high variation. In the radiation
valley region, the c-H2AX signal was initially similar
between the tumor valley and normal valley regions, but
showed significantly higher in tumor valley region starting at
24 h postirradiation. The signal in the tumor valley was 1.38-,
1.61- and 1.92-fold higher than that in the normal valley
region at 24 and 48 h and day 7 after irradiation (P¼ 0.045,
0.038 and P , 0.001, respectively). More interestingly, the
c-H2AX signal differences between peak and valley regions
in tumor reduced dramatically at 48 h and almost diminished
at day 7 after irradiation. The signal ratio between peak and
valley regions in tumor changed from 5.2 at 1 h after MRT to
2.3 at 48 h and 1.1 at day 7 after MRT. Figure 5A shows that
the c-H2AX foci were more dispersed from the beam tracks
to the overall tumor region at 48 h and day 7 after irradiation.
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In contrast, there were still clear separations between peak
and valley regions at 48 h and day 7 after MRT in normal
tissue, although the signal was quite weak at the 7-day time
point. The spreading of c-H2AX signal in the tumor might be
caused by tumor cell migration and possible bystander effect.
MRT on Apoptosis and Cell Proliferation
Figure 6 shows the results of caspase-3 staining on tumor
and normal brain tissue. In the tumor tissue, positive cleaved
caspase-3 signal was initially low, but increased over time in
both the tumor peak and tumor valley regions (Fig. 6A–C).
Interestingly, the difference in apoptosis level between the
peak and valley regions in the tumor decreased significantly
at 48 h and at day 7 after irradiation. The ratio of apoptotic
cells in the peak to that in the valley region was 2.3 at 4 h,
dropping to 1.1 at day 7 after MRT (Fig. 6C). The number of
apoptotic cells was (59 6 12)/mm2 in the peak region and
(55 6 14)/mm2 in the valley region at day 7 in tumor tissue.
The number of apoptotic cells in contralateral normal
brain tissue within the microbeam radiation field was
FIG. 2. Microbeam profiles using Gafchromic films and c-H2AX staining on irradiated brain. The beam
width (FWHM) was 280 lm at the entrance plane on the top of the mouse brain (panel A) and 380 lm at the exit
plane at the bottom of the head (panel B). Normal brain tissue section (panel C) and tumor-bearing mouse brain
(panel D) were stained with anti-c-H2AX antibody at 1 h after microbeam irradiation. Red fluorescence signal
indicates the positive expression of c-H2AX signal. Staining of c-H2AX demonstrated the microbeam radiation
track. The average FWHM of the c-H2AX staining was 343 lm.
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quantified after the low-dose MRT (Fig. 6D). Compared to
the tumor tissue, there was a much lower level of apoptosis
in the normal brain tissue after MRT. Apoptotic cells were
mainly in the microbeam peak region with little to no
apoptotic cells in the valley region (see Supplementary Fig.
S1; http://dx.doi.org/10.1667/RR13919.1.S1). The number
of apoptotic cells peaked at 24 h after MRT (0.66 6 0.12/
mm2) and reduced thereafter in the normal brain tissue.
Apoptosis level was also assessed in normal brain tissue at
24 and 48 h after BRT, and was significantly higher (0.65
6 0.11/mm2) compared with that in the MRT group (0.35
6 0.09 /mm2) at 48 h after irradiation.
Proliferation measurement with Ki-67 staining showed that
tumor proliferation was significantly reduced in the radiation
beam passing region at 1 h after irradiation (average of 15%
drop from the nonirradiated control level), and continued to
drop at 4, 24 and 48 h after irradiation (average of 27, 50 and
70% drop, respectively), as shown in Fig. 7. Tumor cells in
the valley dose region had a lower reduction on proliferation
compared to the radiation beam passing region (3, 9, 28 and
43% drop at 1, 4, 24, and 48 h after MRT, respectively).
However, at day 7 after MRT, tumor proliferation returned to
the level similar to that at 4 h postirradiation. The radiation
beam passing region and radiation valley region at day 7 had
averages of 77 and 83% proliferation levels compared to the
nonirradiated tumor tissue, suggesting tumor regrowth after
MRT.
In the contralateral normal tissue, there was an increase of
cell proliferation after MRT, which peaked at 48 h (Fig. 8).
The proliferation cells were found mainly in the valley region
in the MRT field (see Supplementary Fig. S2; http://dx.doi.
org/10.1667/RR13919.1.S1). Compared to the normal brain
tissue after BRT, there was a dramatically higher level of cell
proliferation in the MRT-treated normal tissue (7.43 6 2.09/
mm2 and 10.64 6 3.41/mm2 for 24 and 48 h, respectively,
for the MRT vs. 0.51 6 0.11/mm2 and 0.50 6 0.11/mm2 for
24 and 48 h, respectively, for the BRT), which was more than
20 times higher at 48 h after irradiation. This higher
proliferation level in the normal brain tissue after MRT
suggests a rapid tissue regeneration process after MRT.
Normal mice without tumor were irradiated with the low-
dose MRT protocol in the forebrain region, and expression
of c-H2AX, caspase-3 and F4/80 on normal brain tissue was
examined at 24 h and day 30 after MRT. Thirty days after
MRT, there were no obvious c-H2AX signal tracks,
FIG. 3. Survival curves of four groups of U87MG-bearing mice,
each with a different treatment. The groups received sham irradiation,
low-dose MRT (48 Gy of peak dose, 280 lm beam width and 900 lm
beam separation), high-dose MRT (72 Gy of peak dose, with the same
beam width and separation) or BRT (10 Gy of conventional broad-
beam radiation).
FIG. 4. Tumor volume measurement using MRI before and after microbeam irradiation. Panel A: T2 weighted MR images at different time
points for the three groups. The white dashed line shows the tumor region contours. Panels B and C: Absolute tumor volume measurement and
volume changes, respectively. Tumor volume was significantly suppressed at day 7 after irradiation in two treatment groups. At day 14 after
irradiation, tumor volume in the high-dose MRT group was significantly lower than that in the sham-irradiated group (*P¼0.04). Low-dose MRT
only showed a trend of tumor suppression at day 14 after irradiation (P¼ 0.21).
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however, low c-H2AX staining signal was found sporad-
ically in the irradiated region. The apoptosis level at 24 h
after MRT on normal mouse brain was 0.41 6 0.07/mm2,
which was much lower than the level at the contralateral
normal brain tissue in the tumor mice (0.66 6 0.12/mm2) (P
¼ 0.08). Thirty days after MRT, the apoptosis level in the
irradiated region dropped to its lowest (0.18 6 0.04/mm2)
compared to all time points examined.
Neither microglial activation nor macrophage infiltration
was found on normal brain at 24 h or day 30 after
irradiation, as shown in F4/80 staining images (Fig. 9).
There was some nonspecific F4/80 staining in the neuron
cells, but no positive staining in microglial or macrophages
compared to a positive control.
DISCUSSIONS AND CONCLUSIONS
This work demonstrates the feasibility of conducting
MRT studies on a glioblastoma multiforme tumor mouse
model using the compact CNT-based image-guided micro-
beam irradiator in a regular laboratory setup. Although this
first-generation device was not ready to generate the ultra-
high dose of hundreds Gy used in synchrotron-based MRT
studies, it has allowed us to produce a typical microbeam
radiation profile and evaluate the MRT effects on both
tumor and normal tissue. Our initial assessment showed that
even at the relatively low-dose level the life span in the two
MRT protocol-treated tumor mouse groups was significant-
ly extended compared to the nontreated, sham-irradiated
group. Although more than half of the tumor volume was in
the valley dose regions, which received lower dose radiation
(less than 5 Gy, calculated with the average PVDR of 15),
the MRT group showed survival similar to that of the 10 Gy
BRT group. Tumor volume growth was greatly suppressed
in the high-dose MRT group in the two-week monitoring
period after irradiation, although it did not result in a
significant extension of survival compared to the low-dose
MRT and BRT group. Mice treated with low-dose MRT
FIG. 5. Gamma-H2AX staining on irradiated tumor and normal brain tissue. Panel A: Changes of c-H2AX
signal at different times after MRT on tumor and normal brain tissue. Microbeam radiation paths were clearly
shown at 1 and 24 h, however, the peak and valley tracks became mixed at 48 h and day 7 on tumor tissue, but
not on normal brain tissue. Panels B and C: Quantified c-H2AX levels. The expression of c-H2AX reduced over
time, indicating a repair process after irradiation. The expression level was similar in the peak region between
tumor and normal tissue, however, there was significantly higher expression of c-H2AX in the tumor valley
region compared to that in the normal valley region at 24 h, 48 h and day 7 after MRT.
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had initial tumor suppression, with tumor regrowth at a later
phase, which was consistent with the Ki-67 staining of
tumor proliferation. Immunostaining of c-H2AX and
cleaved caspase-3 showed higher DNA damage and more
apoptosis in tumor tissue compared to normal brain tissue.
MRT on normal brain tissue caused low apoptosis and little
macrophage infiltration at 30 days after exposure, indicating
that normal brain tissue tolerates well with prescribed MRT.
As a first-generation prototype the performance of the
current device is far from reaching the full potential of the
distributed X-ray source array as a compact MRT irradiator.
However, we have demonstrated that it is capable of
generating microbeam radiation with MRT dosimetric
characteristics, including beam width and PVDR, which
are proven effective as MRT regimen. Although other
studies have shown high therapeutic efficacy with normal-
tissue-sparing effect using synchrotron MRT (6, 8), it is
pivotal to evaluate the MRT effects on animal models with
this compact MRT system, given the differences in MRT
parameters among the systems. The microbeam width used
in the current MRT study was 280 lm, which is wider than
the ones typically used in the early synchrotron MRT
studies (25–90 lm). The width of the microbeam generated
by the compact CNT-MRT is determined by the beam-
forming collimator, which is adjustable in width, and the
width of the X-ray focal line, which is 130 lm in the current
system. Dilmanian et al. proposed a so-called ‘‘mini-beam
radiation concept’’, where radiation beams as thick as 0.68
mm were used for treatment, and demonstrated good normal
tissue sparing in the rat CNS with dose up to 170 Gy (23,
24). Several other studies have also reported the tissue
sparing effect and tumoricidal results from radiation beams
with about 0.6 mm thickness (5, 25). These studies show
that it is not necessary to limit the radiation beam width
below 100 lm to retain normal tissue sparing and tumor
control. Our results and those of others with wider beam
width make more promising the potential clinical applica-
tion of MRT, and also make it more feasible to achieve
high-dose rate in our compact MRT technology.
One limitation of our current MRT system is its relatively
low dose rate. The current system delivers at an average
microbeam dose rate of 1.2 Gy/min, which limits the total
FIG. 6. Immunofluorescence staining of cleaved caspase-3 as cell apoptosis assay. Cleaved caspase-3 signal
is shown in red fluorescence. Red: positively stained cleaved caspase-3 signal; blue: DAPI counterstaining of the
nuclei. Panel A: Low level of apoptosis at 1 h after MRT in tumor tissue. Panel B: Apoptotic cells at day 7 after
MRT in tumor tissue. Panel C: Number of apoptotic cells from 1 h to day 7 after MRT in tumor tissue. There
were significant differences between the peak and valley regions at 4 and 24 h, but not at 48 h and day 7 after
MRT. Panel D: Number of apoptotic cells in the contralateral normal brain tissue after MRT and at 24 and 48 h
after BRT. There was a significantly higher level of apoptosis at 48 h after BRT (*P , 0.05, compared to MRT).
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dose that can be delivered to an anesthetized animal in the
experiment. The peak doses used in the two MRT protocols
were 48 and 72 Gy, much lower than peak doses used in a
typical MRT study in the synchrotron facility. Although we
have not conducted many animal studies with high-dose
MRT due to the limited low dose rate, we have demonstrated
that both MRT protocols extended the life span of tumor-
bearing mice (48.5% and 31.4% increase of life span for
high- and low-dose MRT, respectively). A similar outcome
has been reported in synchrotron-based MRT research.
Prezado et al. recently reported an increased life span of
about 42% on 9L glioma rats treated with unidirectional
MRT (as used in this study) with 100 Gy peak dose, 640 lm
beam width and 1.12 mm center-to-center distance (5). In
their study, the life span was further increased to 100% when
an interlaced microbeam pattern was applied. Nevertheless,
we recognize the need to place dose rate as a top priority in
compact MRT technology development and anticipate that
the second generation CNT MRT system (under construc-
tion) will have a 203 increase in dose rate.
Our study showed that there was low level of normal tissue
damage in normal mouse brain after MRT with the presented
radiation dosage. There was significantly lower number of
apoptotic cells at 48 h after MRT compared to that after 10 Gy
BRT. A low level of apoptosis and no F4/80þ macrophages
were observed at 24 h or day 30 after MRT in normal mouse
brain, indicating good tolerance of brain tissue to the
prescribed MRT. Our current assessment on the normal tissue
damage is limited to DNA damage and apoptosis in this
article. More physiological and functional assays including
blood-brain-barrier and inflammation measurement have been
planned out and will be included in a future study.
Radiation-induced normal tissue damage has been well
documented in conventional radiation treatment. It has been
reported that radiation exposure could cause a significant
amount of apoptosis in rodent brain, especially at the
dentate subgranular zone (SGZ) in a dose-dependent
manner after whole-brain irradiation (26, 27). Neuro-
inflammation has been reported after whole-brain single-
dose irradiation and manifested as activated astrocytes,
activated microglial cells and infiltrated macrophages, as
early as 4 h in vivo (28, 29) and as late as 1 month and 6
months after whole-brain irradiation (30–32). Morganti et
al. reported a significant increase in F4/80þ activated
macrophages in irradiated brains compared to sham-
irradiated brains at day 7, 14 and 28 after 10 Gy cranial
irradiation (32). Moravan et al. reported acute neuro-
inflammation at day 3 after 35 Gy irradiation, and delayed
microglia activation and T-cell infiltration at 1 month after
15 Gy irradiation (30). On the other hand, many studies
have demonstrated normal tissue-sparing effects from the
MRT. Laissue et al. first reported unexpected minor damage
to normal brain tissue after high-dose MRT (312 and 625
Gy peak dose, 100 lm width) (9). Priyadarshika et al.
reported significantly less skin damage, including leukocyte
FIG. 7. Immofluorescence staining of Ki-67 as cell proliferation
assay on tumor after MRT. Examples of Ki-67 staining on tumor
tissue at 1 h (panel A) and 48 h (panel B) after MRT are shown. Red:
positively stained Ki-67 protein associated with cell proliferation;
blue: DAPI counterstaining of the nuclei. White arrows indicate the
radiation beam direction on the tumor tissue. Ratios of proliferation
staining to nonirradiated control are plotted over time for both the
tumor peak and tumor valley region (panel C). The proliferation
continuously decreased in both radiation peak and valley regions from
1 to 48 h, however, it bounced back at day 7 after MRT.
FIG. 8. Number of Ki-67-stained proliferation cells on the
contralateral normal brain tissue after MRT and BRT. A significantly
higher number of proliferation cells were found in the MRT mice, but
not in the BRT mice at 24 and 48 h after irradiation (*P , 0.05,
compared to BRT).
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infiltration, from high-dose MRT (800 Gy) than from high-
dose (44 Gy) BRT (33). Dilmanian et al. reported a study
with MRT on duck embryonic brain and demonstrated that
brain tolerance to microbeam irradiation was about three
times higher than to broad-beam irradiation. There were few
radiation-induced lesions observed with a microbeam dose
of 40–160 Gy in the peak (11). MRT (270 lm beam width,
peak dose of 750 Gy) in a rat spinal cord study resulted in a
loss of oligodendrocytes and myelin in two weeks
postirradiation, but repopulation and re-myelination was
nearly complete in 3 months after MRT. Although ‘‘dose-
volume effect’’ [i.e., tissue-tolerant dose increases when
radiation volume gets smaller (10, 34)] has been a general
explanation, detailed molecular mechanisms and signal
pathways to explain how normal tissue recovers efficiently
from MRT have not been well established. Serduc et al.
reported low damage and quick recovery on the brain
vasculature and blood–brain barrier after low-dose (350 Gy)
MRT, and transient blood–brain barrier breakdown after
high-dose (1,000 Gy) MRT using either intravital micros-
copy (35) or MR imaging methods (36). While this rapid
recovery of normal vascular system has been considered to
be the major contributor to the normal tissue-sparing effects
after MRT, further mechanistic studies to elucidate the
vascular repair process are still needed.
It is hypothesized that normal microvessels damaged in
the beam path can regenerate quickly while tumor
vasculature cannot due to structural and molecular differ-
ences of the tumor vessels (37, 38). Dilmanian et al. also
proposed beneficial bystander effects through the release of
the growth factors after MRT, promoting proliferation,
migration and differentiation of the progenitor glial cells to
produce new functional glial cells (39). However, the exact
pathway, dynamics and essential molecular elements of
bystander effects still require extensive investigation. Our
results showed more than 203 higher cell proliferation
found in the microbeam-treated normal brain compared to
broad-beam-treated normal tissue. Crosbie et al. reported
that normal skin tissue showed increased proliferation
starting from 48 h after MRT as one of the tissue-repairing
processes (40). In our study, we observed an increase in Ki-
67-positive cells beginning at 24 h and continuing 48 h after
MRT of the brain, indicating rapid tissue regeneration and
repair from MRT. The mechanisms of normal tissue repair
and regeneration warrant further investigation.
One interesting finding in this present study is the
spreading of the c-H2AX expression from the radiation
peak region to the valley region at 48 h and day 7 after
irradiation. We also observed that apoptotic cells were
distributed over the entire irradiated tumors at later time
points and not confined within the radiation beam path.
Although the ratio of apoptosis in general is relatively low
compared to other cell lines after radiation treatment (41),
the distribution of the apoptotic cells can be clearly
observed. Two mechanisms that might be attributed to this
phenomenon are cell migration or bystander effect. Crosbie
et al. reported on the different responses between tumor
cells and normal tissue, with results showing that the
irradiated peak and valley zones were indistinguishable in
tumors because of extensive cell migration between the
FIG. 9. Immunohistochemistry staining of F4/80 on normal brain tissue at 24 h and day 30 after MRT. There
were no positively stained macrophages or microglial cells found at either 24 h or day 30 after MRT. No other
morphological brain tissue damage was detected.
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zones (40). Sprung et al. also reported that c-H2AX foci at
later time points did not directly correspond with the
targeted regions, suggesting cell movement or bystander
effects as a potential mechanism for MRT effectiveness.
Kashino et al. showed that the induction of DNA DSBs and
cell migration in glioma cells exposed to MRT in vitro were
mediated by bystander effects (42). Our results are highly
consistent with those studies in terms of indistinguishable
damage in tumor tissue. However, extensive mechanistic
studies are needed in the future.
We have compared the survival time and normal tissue
damage between broad-beam and microbeam radiation
exposure. Due to the much more complex dosimetry in
MRT, biological equivalence of a MRT dose to a seamless
BRT dose for a given tissue is still poorly understood.
Priyadarshika et al. suggested that the integrated dose of
MRT, which is the microbeam dose averaged over the entire
radiation volume, might be more relevant than the peak or
valley dose when compared to broad-beam radiation (33).
Recently, Ibahim et al. conducted serial cell irradiation
studies to evaluate the equivalence between synchrotron
MRT and conventional BRT, and reported that BRT doses
of 3.4 6 0.1 Gy were radiobiologically equivalent to a peak
microbeam dose of 112 Gy (25 lm wide spaced, 175 lm on
center) using clonogenic assays on EMT6.5ch cells (43),
which is much lower than the integrated MRT dose. On the
other hand, the in vitro cell radiation study could not truly
represent in vivo irradiation where possible bystander
effects and vascular network factors might greatly influence
the final efficacy. It is still debatable which dose level of
broad-beam radiation can be used for a comparison with the
MRT study. The dose level of 10 Gy was chosen for BRT in
the study mainly because it has been widely used in small
animal studies with single-fraction conventional radiation
(38, 43, 44). Our study showed that 10 Gy of BRT led to a
survival extension similar to MRT. However, our histology
study indicated that BRT might cause more normal brain
tissue damage than MRT. Apoptosis doubled at 48 h in
normal brain tissue after BRT compared to MRT, although
apoptosis levels in both BRT and MRT groups were very
low (0.65 6 0.11/mm2 vs. 0.35 6 0.09 /mm2, respectively).
In addition, Ki-67 staining revealed the number of
proliferating cells to be 203 higher in the normal tissue
after MRT than after BRT, indicating much more rapid
tissue repairing and recovery after MRT, and thus low
damage to normal tissue functionality. Future studies to
compare MRT to the clinical standard of care for
glioblastoma, i.e., the combination of fractionation radiation
and temozolomide (45), will be needed for a more clinically
relevant comparison in terms of therapeutic efficacy.
The current study is the first to evaluate the radiobiolog-
ical effects on mouse brain tumor using the newly
developed prototype compact CNT-based image-guided
MRT system. This study demonstrated that the MRT
delivered by this compact system produces results in
survival, tumor control and normal brain tissue sparing that
are consistent with results from synchrotron-generated MRT
studies. The findings from this study warrant continued
development of compact MRT technology for mechanistic
studies of this promising therapy.
SUPPLEMENTARY INFORMATION
Fig. S1. Apoptosis in normal brain tissue after microbeam
radiation.
Fig. S2. Proliferation in normal brain tissue after micro-
beam radiation.
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